What is the mechanism of action of Etrasimod-Velsipity?

Etrasimod (Etrasimod) belongs to the sphingosine 1-phosphate (S1P) receptor modulator class of drugs. Its mechanism of action mainly exerts therapeutic effects by regulating the distribution of lymphocytes in the immune system. Velsipity binds with high affinity to S1P receptors 1, 4, and 5, but has minimal activity on S1P3 and no activity on S1P2. This selective binding allows it to regulate immune cell migration while minimizing potential side effects in the heart and other organs.

Specifically,Velsipity can partially and reversibly block the outflow of lymphocytes from lymphoid organs, resulting in a decrease in the number of circulating lymphocytes in the peripheral blood. This mechanism is of great significance in ulcerative colitis (UC) because one of the pathological characteristics of ulcerative colitis is the excessive infiltration of lymphocytes into the intestinal mucosa, triggering inflammatory responses and tissue damage. By reducing the migration of peripheral blood lymphocytes into the intestine, Velsipity may indirectly reduce intestinal inflammation, thereby improving patient symptoms and promoting mucosal healing.

AlthoughVelsipity’s specific mechanism of action in UC has not yet been fully understood, but its selective regulation of S1P receptors provides a theoretical basis. By targeting S1P1, 4, and 5, the drug can control abnormal migration while maintaining the normal immune function of lymphocytes, reflecting the characteristics of immune regulation rather than comprehensive suppression. This may result in better safety and long-term tolerability compared with traditional immunosuppressants.

In addition,Velsipity’s combination of oral controllable dosage and reversibility make it highly flexible in clinical applications. If abnormalities in blood or immune indicators occur, doctors can quickly restore lymphocyte balance by adjusting the dose, thereby reducing the risk of serious adverse reactions. Overseas studies and guidelines have pointed out that Velsipity provides an immunomodulatory treatment option that is both effective and controllable and safe for patients with moderate to severe UC.

Reference materials:https://www.drugs.com/mtm/etrasimod.html